Arrowhead Pharmaceuticals Inc
Research Arrowhead Pharmaceuticals Inc (ARWR) on Bullrun: market cap USD 12.54B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARWR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.54B
- Financial periodQ2 2026
- RevenueUSD 75.25M
- Net income-USD 194.28M
- Free cash flow-USD 181.32M
Valuation Snapshot
latest market cap is USD 12.54B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 829.45M | -USD 1.63M | USD 156.89M | n/a | -0.01 | USD 226.55M | USD 312.77M | USD 466.05M |
| FY2024 | USD 3.55M | -USD 599.49M | -USD 604.32M | n/a | -5 | USD 102.69M | USD 525.27M | USD 185.44M |
| FY2023 | USD 240.74M | -USD 205.28M | -USD 330.63M | n/a | -1.92 | USD 110.89M | USD 118.58M | USD 271.34M |
| FY2022 | USD 243.23M | -USD 176.06M | -USD 188.91M | n/a | -1.67 | USD 108.01M | USD 81.11M | USD 398.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 12.54B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 9.12B | 43.1 | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.36B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.29B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.30B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 6.95B | n/a | n/a | n/a |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arrowhead Pharmaceuticals Inc's market cap?
Arrowhead Pharmaceuticals Inc's market capitalization is USD 12.54B.
What does Arrowhead Pharmaceuticals Inc do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.